A recent clinical trial, BRILLIANCE demonstrated the safety and efficacy of CRISPR gene editing in treating inherited blindness caused by mutations in the CEP290 gene.
BRILLIANCE trial results showed 11 out of 14 treated participants experienced some improvements in vision and quality of life measures.
CRISPR-based therapy
Results from a groundbreaking clinical trial of CRISPR gene editing in 14 individuals with a form of inherited blindness show that the treatment is safe and led to measurable improvements in 11 of the participants treated.
CAMBRIDGE, Mass., May 02, 2024 Editas Medicine, Inc. , a clinical-stage gene editing company, today announced that it will host a conference call and webcast on Wednesday, May 8, 2024, at 8:00.
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseasesCAMBRIDGE, Mass., May 01, 2024 Editas Medicine, Inc. , a.